Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate in severe ankylosing spondylitis: an open study

M C Creemers1, M J Franssen, L B van de Putte

  • 1Department of Rheumatology, St. Radbound Academic Hospital Nijmegen, The Netherlands.

The Journal of Rheumatology
|June 1, 1995
PubMed
Summary

Methotrexate (MTX) showed beneficial effects for most patients with ankylosing spondylitis (AS) who did not respond to other treatments. Side effects were mild and reversible, indicating MTX is a viable treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Fewer caesarean sections for breech presentation following external cephalic version according to a protocol in a special office visit].

Nederlands tijdschrift voor geneeskunde·2008
Same author

European genetic study on rheumatoid arthritis: is there a linkage of the interleukin-1 (IL-1), IL-10 or IL-4 genes to RA?

Clinical and experimental rheumatology·2002
Same author

Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis.

The American journal of pathology·2001
Same author

The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.

Arthritis and rheumatism·2001
Same author

[Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].

Nederlands tijdschrift voor geneeskunde·2001
Same author

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.

Annals of the rheumatic diseases·2001

Area of Science:

  • Rheumatology
  • Pharmacology

Background:

  • Ankylosing spondylitis (AS) is a chronic inflammatory disease.
  • Treatment options for AS include NSAIDs and sulfasalazine, but some patients do not respond adequately.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of methotrexate (MTX) in patients with active ankylosing spondylitis.
  • To assess MTX as a treatment for patients refractory to NSAIDs and sulfasalazine.

Main Methods:

  • An open-label, single-observer study involving 11 patients with active AS.
  • Patients received oral methotrexate (7.5-15 mg weekly) for at least 24 weeks.
  • Efficacy was measured by changes in assessed variables and patient evaluation.

Main Results:

Related Experiment Videos

  • Significant improvement in assessed variables was observed.
  • Four patients continued MTX, with some reducing NSAID dosage.
  • Mild and reversible side effects were reported; 3 patients discontinued MTX due to disease flares but later restarted.

    • Conclusions:

    • Methotrexate demonstrated beneficial effects for the majority of ankylosing spondylitis patients studied.
    • MTX appears to be an effective and well-tolerated treatment option for AS patients unresponsive to conventional therapies.